Phase 3 Clinical Study of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia

Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225142

Enrollment

Registered

2020-03-27

Start date

2020-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with COVID-19 non-severe pneumonia

Interventions

investigational material(s) Generic name etc : Favipiravir (T-705) INN of investigational material : Favipiravir Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Age: 20 to 74 years inclusive 2.Sex: No restriction 3 Out patient/hospitalization: Hospitalization 4 Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. 5 Lung involvement confirmed with chest imaging 6 Patients with fever of 37.5 degrees Celsius or more 7 Have a negative pregnancy test before study treatment 8 Others

Exclusion criteria

Exclusion criteria: 1 Ten days or more have passed since the fever (37.5 degrees Celsius or more) started. 2 Patients who are pregnant or may be pregnant 3 Patients with severe hepatic or renal impairment 4 Others

Design outcomes

Primary

Measure	Time frame
efficacy Time to alleviation of body temperature, SpO2, and chest image findings, and time to SARS-CoV-2 RT-PCR negativity.	—

Secondary

Measure	Time frame
safety efficacy Safety:Adverse events Efficacy:Change in patient condition on a 7-piont scale	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026